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1. Introduction
  The 5-year survival rate of advanced ovarian carcinoma is 
less than 30%, and on the contrary, the 5-year survival rate 
of early ovarian carcinoma may be up to 90%. Therefore, 
early diagnosis is the key to improve prognosis of ovarian 
carcinomas. As a new tumor marker, the application 
of human epididymal secretory protein E4 (HE4) in 
differential diagnosis of ovarian carcinoma has been 
confirmed[1]. At present, there has been new recognition 
concerning pathology of ovarian carcinomas, ie. theories 
of “dualistic pathology model”[2,3] and “heterogeneity 
of ovarian carcinomas”[4,5] for pathogenic mechanism 
of ovarian carcinomas. In the past, it has been said that 
ovarian carcinomas originate from ovary itself, ie. ovarian 
surface epithelium, have the potential for multi-lineage 
differentiation, and so may form histological types of 
ovarian tumors, in which serous cystadenocarcinoma is 
the most common. For the “dualistic pathogenesis”, the 
core is the theory of external origin for ovarian carcinoma, 
in which it is said that ovarian carcinomas are irrelevant 
to ovarian surface mesothelium cell, but from plantation 
outside the ovary. For example, serous tumor is from 
oviduct mucosa epithelium, endometrioid carcinoma and 
clear cell tumor are from ectopic endometrium, mucinous 
tumor and transitional cell carcinoma possibly from para-
ovarian Wathard cell nest. Different ovarian carcinomas 
have different origins. This opinion and the theory of 
“ovarian carcinomas heterogeneity” supplement each other. 
According to the latter, epithelial ovarian carcinomas are not 
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a single disease, but a set of diseases of “heterogeneity”[5]. 
Furthermore, from the molecular view point, the epithelial 
ovarian cancer may be divided into subtypes 栺 and 栻. 
Low grade serous carcinoma (LGSC) and high-grade serous 
carcinoma (HGSC) are typical subtypes 栺 and 栻 ovarian 
carcinomas, respectively[6]. The two are significantly 
different in biological behaviors and clinical features[7]: 
subtype 栺 tumor is inert in biological behavior, and the 
disease will experience a progressive process of ovarian 
epithelial inclusions-serous cystadenoma-borderline 
cystadenoma-low grade serous cystadenocarcinoma. 
Usually, the disease is at an early stage; subtype 栻 tumor 
is characterized as high invasiveness, and is almost always 
at advanced stage once found. Two subtypes are different in 
characteristics of molecular genetics: the genetic mutations 
of KRAS and BRAF etc. occurring in about two thirds of 
subtype栺 tumor cases, while TP53 mutation was rare; more 
than 80% of subtype 栻 tumor cases were found with TP53 
mutation and CCNE1(code: cyclin E1) augmentation. As for 
the prognosis, among the dead cases of ovarian carcinomas, 
25% were of subtype 栺 ovarian carcinomas, while 75% 
were of subtype 栻 tumor. Therefore, for serous carcinoma, 
HGSC and LGSC are two diseases different in biological 
behavior, pathological mechanism and prognosis though 
both are serous carcinoma in histology. In recent years, 
the application of two-tier grading system (also known as 
MDACC grading system)for ovary serous carcinoma attracted 
attention[8]. According to traditional three-tier grading 
system, different grades of ovary serous carcinoma have 
the same route of tumor occurrence, which cannot reflect 
the “heterogeneity” of ovarian carcinomas, while two-
tier grading system is identical to the dualistic model for 
occurrence of ovary serous carcinoma, and can guide clinical 
prognosis[9]. The ultimate goal of differential diagnosis for 
diseases is to identify diseases different in pathology, type, 
and prognosis, but identical in clinical manifestation, so as 
to further guide relevant therapy and prognosis. According 
to relevant data, diagnosis of ovarian carcinomas based on 
heterogeneity is more scientific. 
  Present study also showed high expression of HE4 
serous carcinoma and relative low expression of clear cell 
carcinoma and mucinous ovarian carcinoma[10], which 
indicated that HE4 was different in diagnosis of different 
histopathological types. However, at present there is still 
no literature concerning study on difference of HE4 in low 
grade LGSC and high grade HGSC of serous carcinoma. 
According to two-tier grading system, high differentiation 
serous carcinoma and ovarian endometriocarcinoma are 
of subtype 栻 cancer, clear cell carcinoma and mucinous 
ovarian carcinomas are of subtype 栺 cancer, which 
indirectly indicate that we should make clear whether there 
is different expression of HE4 between subtype 栺 and 
subtype 栻 cancers, annd whether this difference leads to 
differential diagnosis of subtype 栺 and subtype 栻 cancers. 
In this study, the “two-tier grading system” is used to 
find out the difference of HE4 in tissue and serum between 
LGSC and HGSC, as well as the significance in differential 
diagnosis. 
2. Materials and methods 
2.1. Subject 
  B e t w e e n  N o v e m b e r  2 0 1 1  a n d  M a y  2 0 1 2 ,  6 0 
cases pathologically diagnosed as serous ovarian 
cystadenocarcinoma after operation, who were hospitalized 
for pelvic mass were selected. According to two-tier grading 
system for ovary serous cystadenocarcinoma (MDACC 
grading), they were divided into subtype 栺 LGSC and 
subtype栻HGSC. And the standard for grading was as Xia et 
al[11]. According to main standard based on morphology of 
tumor cell nucleus, they were divided into LGSC and HGSC. 
The low grade nucleus had characters of slight to moderate 
heteromorphosis, relative identical size, round or oval 
shape, exquisite chromatin, even distribution, and visible 
nucleolus; the high grade nucleus was characterized as 
severe heteromorphosis, different sizes and shapes, coarse 
chromation, obvious nucleolus, with difference between 
nucleus sizes≥3: 1; for the morphological evaluation of cell 
nucleus, the region with the most obvious atypia should be 
selected. Secondary standard based on mitotic count: low 
grade≤12/10 HPF, high grade>12/10 HPF; the counting 
method was as follows: for region with the most active mitotic 
figures, counted 10 continuous high power fields (400×), 
repeated for 4 times, with the one with the most quantity of 
mitotic figures as the counting result. At the same time, took 
mutation P53 albumen as the control index. Mostly, subtype 
栻 was positive in P53 diffusion, while subtype 栺 P53 focal 
positive or negative[9]. The study has been approved by the 
hospital ethical committee and the patients had informed 
consent right. 
2.2. Methods
  The kit for two-step immunohistochemical assay of mouse 
anti human HE4 monoclonal antibody and mouse anti human 
TP53 monoclonal antibody and the DAB color development 
kit were purchased from Beijing Zhongshan Biological 
Technology Co., LTD. The steps for immunohistochemical 
staining were performed according to the instruction for use 
of kit, with the known positive piece as the control (with 
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HE4 as ovarian carcinomas, and P53 as breast cancer), and 
PBS solution as substitute of the primary antibody for blank 
control. 
  For the serum HE4 enzyme-linked immunosorbent assay 
(ELISA Double Antibody Sandwich Method), the assay kit 
was purchased from Fujirebio Diagnostics, Inc of Sweden 
(Catalog Number 404-10K), unit of concentration: pmol/L, 
reference value 0-150, instrument: Full automatic enzyme 
immunoassay analyzer of TECAN Freedom Evolyzerl50. 
For serum CA125 content, the isotope analyzer and original 
reagents from the Laboratory Department of our institute 
were adopted, if serum CA125 value >30.0 IU/mL, the 
result was positive. Before operation, 2 mL of venous blood 
was taken from patients, without hemolysis or lipoidemia, 
and was under 4 000 g centrifugation for 5 min. Serum was 
collected and placed in -70 ℃ refrigerator for storage. 
  Yellow grain or mass in cytoplasm of tumor cell indicated 
positive staining of HE4 and TP53 and was measured by a 
twice- scoring method. Five fields of spot and the region 
with the densest carcinoma tissues was counted under 
400× light microscope, and the average was taken as the 
intermediate density of this target albumen. Five high power 
fields was randomly counted, and average positive rate as 
well as proportion of positive cells in each high power field 
was calculated. For immunohistochemical semiquantitative 
analysis, a “13-point” scoring method was used: 0 for 
colorless, 1 for light yellow, 2 for brown yellow, and 3 for 
brown. Then it was scored based on proportion of positive 
cells: 0 for without positive cells, 1 for positive cells <10%, 2 
for positive cells 10%-50%, 3 for 50%-80%, and 4 for >80%. 
Finally, all the scores for staining strength and for positive 
cells were added for judging the expression results: scores 
<2 negative, >2 positive, 4-5 moderate positive, 6-7 strong 
positive. 
2.3. Statistical analysis
  For the categorical data analysis method, chi-square 
test for paired fourfold data was adopted, and in the test, 
the samples should be more than 40, and in each grid, the 
theoretical frequency T≥5. If the samples are more than 40 
but the theoretical frequency T< 5, a continuous correction 
formula was used for the chi-square value. If T< 1, the 
exact probability method should be used for calculation of 
probability. For numeric data analysis, if the data follow the 
normal distribution, the mean依standard deviation should 
be used for description, and for comparison between the 
two, group t test should be used. For abnormal distribution, 
percentile was used for description and rank sum test was 
used. Kappa index reflects consistency between indexes. If 
Kappa>0.75, the consistency is good, and Kappa <0.4, the 
consistency is poor. 
3. Results
3.1. Grading
  LGSC revealed micro papilla structure, with cell nucleus 
light to moderate heteromorphosis, except for 1 case, mitotic 
figures <12 /10HPF (average 6/10HPF). For HGSC, borderline 
lesion transitional region was not observed, 98% of the 
cases revealed major papilla, fissure like or solid laminate 
structure, with significant heteromorphosis of cell nucleus, 
and for all, mitotic figures >12/10HPF(average 37/10HPF) 
(Figure 1, 2). 
1                                                                      2
Figure 1. Morphology of 栺/栻 HGSG.
1. HGSG exhibits moderate to marked nuclear atypia. 2. On high 
power , abundant mitotic activity (arrow), greater than 12 mitoses per 
10 high power fields (1.HE×100,  2. HE×400).
1                                                                      2
Figure 2. Morphology of 栺LGSG.
1. LGSG was characterized by a micropapillary architecture and clefts 
surrounding the groups of tumour cells. 2. On high power ,the uniform 
nuclei with mild atypia and less to 12 mitoses per 10 high power fields 
(1.HE×200, 2. HE×400).
  According to two-tier grading, among 60 cases with 
ovary serous carcinoma, there were 19 LGSC cases, and 41 
HGSC cases. According to WHO grading, among 19 cases 
with LGSC, 9 cases (47.4%) were of WHO栺 grade, 10 cases 
(52.6%) of WHO栻 grade; while among 41 cases with HGSC, 
24 cases were of (58.5%) WHO栻 grade, 17 cases (41.5%) of 
WHO 栿 grade. Among 19 cases with LGSC, there were 16 
at FIGO stage栺-栻 and 3 at stages 栿 or higher; in HGSC 
patients, there were 5 at FIGO stage栺-栻 and 36 at stages 栿 
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or higher. It indicated that there was significant difference 
between LGSC and HGSC in FIGO staging (氈2= 29.60, 
P<0.01). 
3.2. TP53 and HE4 immunohistochemical results
  In serous carcinoma, the total positive rate of HE4 was 
93.33% (56/60), the positive rate of HGSC group was 100% 
(41/41), and positive rate was 78.94% in LGSG group (15/19). 
There was statistical significance for the difference (氈2= 
39.05, P <0.01). Kappa= 0.837 indicated good consistency of 
HE4 albumen expression and 栺/栻 classification. 
  The strong positive rate of P53 was respectively 10.3%(2/19) 
in LGSG group and 92.7%(38/41) in HGSG group with 
significant difference (Pearson 氈2= 39.43, P<0.01). 
Kappa=0.810>0.75 indicated good consistency of P53 
albumen expression and 栺/栻 classification. For subtype 
栻 serous carcinoma tumor cell nucleus, the P53 albumen 
expression was diffusely positive, while for subtype栺cancer 
tissues, the focal of TP53 albumen was positive or negative 
(Figure 3-5). 
1                                                                      2
3
Figure 3.  Diffusive positive expression of HE4 protein in type 栻 
serous ovarian tissue. 
1, 2: SP×200; 3: SP×400.
1                                                                      2
Figure 4. Week positive expression of HE4 protein in type栺serous 
ovarian tissue.
1: SP×200; 2: SP×400.
1                                                                      2
3
Figure 5.  Diffusive positive expression of TP53 protein in HGSG 
serous ovarian tissue. 
1: SP×100; 2:×200; SP3: SP×400.
3.3. Difference between LGSC and HGSC in serum HE4 and 
CA125
  Homogeneity test of variances of samples showed 
homogeneity of variances in HE4 (F=3.033, P=0.087) and 
CA125 (F=0.786, P=0.379). Normal distribution QQ test also 
revealed normal distribution. Independent t test showed the 
serum HE4 level was (408.23依78.84) pmol/L in HGSC group 
and, and (288.11依59.52) pmol/L in LGSC group (t=-5.898, 
P<0.01); serum CA125 level in HGSC group was (475.74依
202.34.84) U/L, and in LGSC group (637.0224依324.98 U/L) (t= 
- 1.987, P=0.052). 
4. Discussion
  Presents, all literatures indicated the value of HE4 in 
differential diagnosis and early diagnosis of ovarian 
carcinoma, but the literatures followed WHO histological 
classification and FIGO staging, and failed to further 
analyzed the serous cystadenocarcinoma by subtypes of 
HGSC and LGSC. It has been proved that HGSC and LGSC are 
two diseases different in biological behavior, pathological 
mechanism and prognosis though both are serous carcinoma 
in histology[6]. Therefore, present literatures failed to be 
based on “dualistic pathogenesis model”, and failed to 
reflect the “heterogeneity”. Therefore, it is necessary to 
study the expression difference of HE4 HGSC and LGSC. 
  This study found that there was expression difference of 
HE4 in tissues and serum between LGSG and HGSG, which 
indicated that HE4 might conduce to differential diagnosis of 
LGSG and HGSG. For serum CA125, there was no expression 
difference between LGSG and HGSG, which indicated that 
CA125 was not helpful in differential diagnosis of LGSG and 
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HGSG. This resulted in a thought concerning selection of 
control index in present diagnostic test: CA125 diagnosis is 
lack of sensitivity and specificity for ovarian carcinomas, 
which has been recognized. This study further found that 
there was no difference for CA125 expression in LGSG and 
HGSG, which indicated that CA125 might have no value in 
subtype diagnosis of ovarian carcinomas. This is identical 
to the results reported. Mao et al reported that CA125 had no 
effect on differentiation between high grade and low grade 
serous epithelial ovarian carcinomas[12]. It was proved that 
9 serum tumor markers like CA125 showed no difference in 
expression of different subtypes of (subtype 栺, subtype 栻)
ovarian carcinomas[13], which indicated that for evaluating 
the value of HE4 in differential diagnosis, CA125 was not 
an ideal control index. There was difference in P53 genetic 
mutation for subtype 栺 and 栻 ovarian carcinomas, and 
some relevant studies showed good correlation of serum 
p53 antibody ( p53AAbs)with ”two - tier grading system”, 
which indicated that p53AAbs might be more appropriate as 
diagnosis control of subtype 栻 “ ovarian carcinomas”. The 
inert biological behavior of subtype 栺 ovarian carcinomas 
showed relative inert and progressive, and limited to ovary. 
So when the disease was found, it was usually still at early 
stage by clinical staging, and it was easy to be found through 
intravagianal ultrasound and pelvioscopy[3], which indicated 
that intravagianal ultrasound may be more appropriate 
as diagnosis control of subtype 栺 “ovarian carcinomas”. 
However, all present literatures took CA125 as the control 
in evaluating the value of HE4 in diagnosis, and so future 
studies should pay attention to setting of more scientific 
control, which is worth discussing. 
  This study found that although there was difference of HE4 
albumen expression in tissues and serum between LGSG and 
HGSG, there was no difference at early stage FIGO (stage栺+栻 ),
which indicated that the value of HE4 in early diagnosis of 
subtype ovarian carcinomas was still to be further studied. 
  In early diagnosis concerning subtype 栻 “small size 
ovarian carcinomas”, we found that FIGO staging of LGSG 
featured stages 栺-栻 while of HGSG featured stages 栿 -桇.
Pilot studies showed that FIGO staging could influence HE4 
level, and the serum HE4 was higher at stages 栿-桇 than at 
stages 栺-栻. Therefore, it is necessary to analyze HE4 level 
within the same FIGO, so as to eliminate the interference. 
However, when we analyzed within FIGO (栺+Istage 栺 ), 
we found that in serum HE4 level there was no significant 
difference between LGSG and HGSG, which indicated that 
serum HE4 might be helpless in differential diagnosis of 
early stage subtype 栺 and subtype栻 ovarian carcinomas. 
The reasons might be as follows: 1) HE4 is a secretory type 
albumen, and the mechanism for secretion into blood is still 
unclear. Accordingly, it was speculated that at stages 栺 and 
栻, the tumor vasculature had not been fully formed, and so 
release in blood was limited. 2) In cases of “early stage ” 
by FIGO grading, the proportion with subtype 栻 cancer was 
low (15%), which was identical to biological characteristics of 
subtype 栻 cancer which progress rapidly[6]. The proportion 
of cases with subtype 栺 ovarian carcinomas was high while 
with subtype 栻cancer was low, which was identical to the 
conclusion of present study. Obviously, this is not good for 
discussion on value of early diagnosis for subtype 栻 ovarian 
carcinomas. Therefore, at present, the value of HE4 for 
diagnosis of subtype 栻 tumor cannot be appraised. 
  Present literatures overestimated the value of HE4 for early 
diagnosis, and so it is necessary to analyze the rationality 
of the study designs and conclusions for these literatures. 
As a whole, early diagnosis for ovarian carcinomas is a 
great challenge, and it is difficult to use a single method to 
include early diagnosis of serum tumor markers. Locally, 1) 
The concept concerning basis on “dualistic pathogenesis 
model”, and “early diagnosis” is unclear. Traditional early 
diagnosis is based on a concept that ovarian masses should 
be first formed for ovarian carcinomas, while according to 
dualistic pathogenesis model (dualistic model) of ovarian 
carcinomas, serous carcinoma is not originated from ovary 
itself, but from secondary planting of cells at fimbriae tubae. 
Therefore, when the tumor has violated the ovary, it has 
been metastatic carcinoma, not primary cancer. Accordingly, 
some scholars questioned the concept of “early diagnosis” 
for ovarian carcinomas, and proposed that “early diagnosis 
of ovarian carcinomas” should be replaced by “diagnosis 
of small size ovarian carcinomas[7]. From the view point of 
“dualistic pathogenesis model”, early diagnosis should be 
from the tubal intraepithelial carcinoma. Now the tumor 
vasculature has not been fully formed, and so release in 
blood was limited. Therefore, the significance of serum tumor 
markers, including HE4 early diagnosis is still to be proved. 
How early should be for “early stage ”? Most literatures took 
stage FIGO (栺+栻) as the standard of early stage, which is 
not necessarily reasonable. Although the concept of “small 
size ovarian carcinomas” has been put forward, but how 
small is small? There is still no specific quantitative criteria. 
2) The “heterogeneity”of ovarian carcinomas and the key 
for early diagnosis was not reflected. The purpose of early 
diagnosis is early detection and treatment at early stage, by 
which the mortality may be reduced finally. From the view 
point of “heterogeneity” theory for ovarian carcinomas, 
subtype I ovarian carcinomas tumor grows slowly, mostly 
is limited to ovary, and only 25% of cases dead for ovarian 
carcinomas resulted from this tumor, while 75% resulted 
from subtype 栻ovarian carcinomas, which is seldom limited 
once occurs, progresses rapidly, with poor prognosis, and 
is difficult to be found by early diagnosis. Therefore, the 
study on early diagnosis should focus on subtype 栻cancer[7] 
(including HGSG). Present literatures failed to reflect this. 
  Therefore, our study, after a comprehensive analysis 
on the literatures, may only consider that HE4 is more 
sensitive and specific than CA125 in differentiating masses 
in terms of benign and malignancy, but the value of HE4 
in early stage diagnosis of ovarian carcinomas cannot be 
directly indicated. The conclusions of present literatures, 
which overestimated the value of HE4 in early diagnosis 
of ovarian carcinomas, should be treated with discretion. 
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Our suggestion is that future studies should be based on 
heterogeneity of ovarian carcinomas, enlarge the sample 
size, and focus on evaluating the value of HE4 in early 
diagnosis of ovarian carcinomas. 
  Most cases at stage FIGO (栺+栻)of ovarian carcinomas 
incorporated in this study were of subtype 栺 serous 
carcinoma (76.1%), and rare cases were of subtype 栻
(13.9%), which conforms to present epidemiological data 
and biological characteristics of subtypes栺 and 栻 ovarian 
carcinomas[7]. The inert biological behavior of subtype I 
ovarian carcinomas showed relative inert and progressive, 
and limited to ovary, and so when the disease was found, 
it was usually still at early stage by clinical staging, and it 
was easy to be found through intravagianal ultrasound and 
pelvioscopy, and so serum indexes are not of top priority[7]. 
The subtype 栺 ovarian carcinomas found in this study have 
pelvic masses to different extent, and the B type ultrasound 
indicated possibility of ovarian tumor, which indicated that, 
1) The literatures overestimated the value of HE4 in early 
diagnosis, and maybe the deviation occurred because most 
incorporated cases at FIGO (栺+栻) were of subtype I tumor. 
2) For control set for evaluating the true value of HE4 in 
diagnosis of subtype 栺“small size ovarian carcinomas”, 
the transvaginal ultrasonography might be more reasonable 
than CA125, which is lack of specificity. Recently, 
a prospective study[14] compared the risk of ovarian 
malignancy algorithm constructed based on serum HE4 
and CA125 with transvaginal ultrasonography for diagnosis 
of ovarian carcinomas in value, and the results were that 
subjective diagnosis based on transvaginal ultrasonography 
was superior to risk of ovarian malignancy algorithm, which 
also indicated that whether HE4 is superior to traditional 
ultrasonography in diagnosis of subtype 栺 ovarian tumor is 
still to be further discussed. 
  In conclusion, ovarian carcinomas are of disease of 
“heterogeneity”. Our study indicated that serum CA125 
cannot distinguish subtype 栺 and subtype 栻 ovarian 
carcinomas, and so is not an ideal control for study of early 
diagnosis by HE4. serum HE4 level might have significance 
in differential diagnosis of subtype 栺 and subtype 栻 
ovarian carcinomas. However, in early stage cases of FIGO 
(stages 栺 + 栻 ), there was no difference of serum HE4 level 
between the two subtypes of ovarian carcinomas, and at the 
same time, at early stage, the proportion with subtype 栻 
“small size ovarian carcinomas” was relative low, and so the 
value of serum HE4 for early diagnosis of subtype 栻 “small 
size ovarian carcinomas” was not sure. Our suggestion is 
that future studies should be based on heterogeneity of 
ovarian carcinomas, enlarge the sample size, and focus on 
evaluating the value of HE4 in early diagnosis of type 栻
ovarian carcinomas. 
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